By Suherman Candra Maholtra 
In a landmark retrospective analysis that could fundamentally alter the preventative approach to non-melanoma skin cancer, researchers have discovered that nicotinamide, a specific form of Vitamin B3, offers substantial protection against the development of new skin malignancies. The study, which analyzed the medical records of more than 33,000 veterans, provides the most robust evidence to date that early intervention with this low-cost supplement can reduce the risk of skin cancer by more than half in certain patient populations. While dermatologists have cautiously recommended nicotinamide for nearly a decade, these new findings from the Vanderbilt University Medical Center and the Department of Veterans Affairs (VA) Tennessee Valley Healthcare System suggest that the timing of treatment is far more critical than previously understood.
The Evolution of Nicotinamide in Preventative Dermatology
The medical community’s interest in nicotinamide—also known as niacinamide—gained significant momentum in 2015 following the publication of the Oral Nicotinamide to Prevent Actinic Keratoses (ONTRAC) trial in the New England Journal of Medicine. That study, which followed 386 participants, demonstrated that 500 milligrams of nicotinamide taken twice daily reduced the incidence of new non-melanoma skin cancers by 23% over a 12-month period.
However, the ONTRAC trial, while influential, was limited by its relatively small sample size and specific focus on patients who had already developed at least two skin cancers in the previous five years. For years, clinicians struggled to determine if these benefits translated to the broader population or if the supplement remained effective over longer durations and across different stages of skin cancer progression. Because nicotinamide is available over the counter as a dietary supplement, tracking its use through traditional electronic health records (EHR) has historically been a challenge for researchers, as patients often do not report supplement use, and physicians rarely code for it in a way that is easily searchable in large datasets.
To bridge this data gap, a research team led by Lee Wheless, MD, PhD, an assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center, turned to the Veterans Affairs Corporate Data Warehouse. Unlike most private healthcare systems, the VA includes nicotinamide on its official formulary, meaning it is prescribed and tracked with the same rigor as pharmaceutical drugs. This unique administrative structure allowed the team to assemble a massive cohort of 33,833 veterans, providing a level of statistical power that was previously unattainable.
Understanding the Biological Mechanism of Vitamin B3
To appreciate the significance of the study’s findings, it is essential to understand how nicotinamide functions within the skin. Non-melanoma skin cancers, which primarily include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are largely driven by DNA damage caused by ultraviolet (UV) radiation. UV exposure leads to two major cellular crises: the direct mutation of DNA and the depletion of cellular energy.
When skin cells are exposed to UV light, they require significant amounts of adenosine triphosphate (ATP) to power DNA repair enzymes. However, UV radiation simultaneously inhibits the production of ATP and depletes nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for energy metabolism. Nicotinamide serves as a precursor to NAD+. By supplementing with Vitamin B3, patients essentially provide their skin cells with the "fuel" necessary to repair UV-induced genetic damage before it can progress into a malignancy. Furthermore, nicotinamide has been shown to reduce the immunosuppressive effects of UV radiation on the skin, allowing the body’s local immune system to better identify and eliminate precancerous cells.
Analysis of the VA Study Results: A Dramatic Shift in Efficacy
The research team categorized the 33,833 veterans into two groups: 12,287 who received a baseline treatment of 500 milligrams of nicotinamide twice daily for at least 30 days, and 21,479 who did not. The results revealed an overall 14% reduction in skin cancer risk among the nicotinamide users across the entire cohort. While a 14% reduction is clinically significant for a common condition, the most striking data emerged when the researchers analyzed the timing of the supplement’s initiation.
For veterans who began taking nicotinamide immediately after being diagnosed with their very first skin cancer, the risk of developing a subsequent malignancy plummeted by 54%. This suggests a "window of opportunity" where the supplement is most effective at halting the cascade of "field cancerization"—a process where large areas of skin become predisposed to multiple tumors due to chronic sun damage.
Conversely, the study found that the protective benefits of nicotinamide began to wane if the treatment was started only after a patient had already developed multiple skin cancers. This finding challenges the current clinical status quo, where many dermatologists wait until a patient is "high-risk" (having multiple annual surgeries) before suggesting the supplement.
The data also highlighted a disparity in efficacy between cancer types. The protective effect was most pronounced for cutaneous squamous cell carcinoma (SCC), which is generally considered more aggressive than basal cell carcinoma (BCC) due to its higher potential for metastasis. The ability of nicotinamide to specifically target SCC pathways marks it as a vital tool in reducing the morbidity associated with advanced non-melanoma skin cancers.
The Challenge for Immunocompromised Populations
The study also delved into a particularly vulnerable subgroup: 1,334 patients who were immunocompromised due to solid organ transplants. Transplant recipients are at a vastly higher risk for skin cancer—sometimes up to 100 times higher than the general population—due to the long-term use of immunosuppressant drugs required to prevent organ rejection.
In this specific group, the overall risk reduction provided by nicotinamide did not reach statistical significance. However, a nuanced look at the data showed that early use was still linked to a decrease in SCC cases. The lack of a broad preventative effect in this group suggests that the mechanisms of cancer development in the immunocompromised may be too aggressive for nicotinamide to counter alone, or that the dosage and timing requirements for these patients are different from those with intact immune systems.
Clinical Implications and Expert Reactions
The findings have sparked immediate discussion among dermatology professionals regarding the update of clinical guidelines. Dr. Lee Wheless emphasized that the study provides a compelling argument for moving prevention strategies "upstream."
"There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population," Dr. Wheless noted. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier. We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers."
The implication is that nicotinamide could transition from a "rescue" supplement for severe cases to a standard preventative measure for any patient who presents with their first non-melanoma skin cancer. Given that nicotinamide is inexpensive, widely available, and possesses a favorable safety profile—notably lacking the "flushing" side effect associated with other forms of Vitamin B3 like niacin—it represents a high-value, low-risk intervention for public health.
Economic and Public Health Impact
From a public health perspective, the potential cost savings are immense. Non-melanoma skin cancer is the most common form of cancer in the United States, with millions of cases diagnosed annually. The financial burden on the healthcare system, and specifically the VA system, is substantial, involving costs for biopsies, surgical excisions (such as Mohs micrographic surgery), and follow-up care.
By reducing the recurrence rate by 54% in early-stage patients, the implementation of nicotinamide protocols could save the VA and private insurers millions of dollars in surgical costs. Moreover, for the veteran population—many of whom were exposed to high levels of UV radiation during service in desert or maritime environments—this intervention offers a significant improvement in quality of life by reducing the frequency of painful and disfiguring procedures.
Future Research and Limitations
While the VA study is the largest of its kind, researchers acknowledge certain limitations inherent in retrospective data. The study relied on pharmacy records, which confirm that the medication was dispensed, but cannot guarantee 100% patient adherence. Additionally, while the VA population is diverse, it is predominantly male, meaning further research may be needed to confirm if the 54% risk reduction is identical in female populations, though biological mechanisms suggest it should be.
The research team, which included Vanderbilt co-authors Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas, was supported by a Department of Veterans Affairs grant. Their work sets the stage for prospective clinical trials aimed at refining the "early-start" protocol.
Conclusion: A New Standard for Skin Cancer Prevention
The Vanderbilt-VA study serves as a pivotal turning point in dermatological oncology. By demonstrating that nicotinamide’s efficacy is tied to early intervention, the research provides a clear roadmap for physicians: the best time to prevent the second skin cancer is immediately after the first. As the medical community digests these findings, a shift in standard-of-care guidelines appears likely, potentially establishing Vitamin B3 as a cornerstone of skin health for millions of aging adults and veterans. The transition from reactive treatment to proactive, supplement-based energy replenishment in the skin marks a sophisticated evolution in the fight against the world’s most prevalent cancer.